News

MD Anderson and Obsidian Therapeutics announce FDA Clearance of IND application for novel TIL therapy OBX-115

July 21, 2022

Read More

Obsidian Therapeutics to Participate in a Panel at William Blair Biotech Focus Conference 2022

July 11, 2022

Read More

Obsidian Therapeutics to Participate in the Truist Securities Cell Therapy Symposium

June 28, 2022

Read More
ABOUT US

We are pioneers in cell and gene therapy

Leading the next generation of engineered therapeutics

Read More

Our Platform

Our proprietary
cytoDRiVE platform

Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule

Read More

OBSIDIAN CAREERS

Join Our Team

Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.

 

Read More